Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

1. Maintenance treatment with antipsychotic drugs for schizophrenia. (Abstract)

Maintenance treatment with antipsychotic drugs for schizophrenia. The symptoms and signs of schizophrenia have been linked to high levels of dopamine in specific areas of the brain (limbic system). Antipsychotic drugs block the transmission of dopamine in the brain and reduce the acute symptoms of the disorder. An original version of the current review, published in 2012, examined whether antipsychotic drugs are also effective for relapse prevention. This is the updated version of the aforesaid (...) review.To review the effects of maintaining antipsychotic drugs for people with schizophrenia compared to withdrawing these agents.We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials including the registries of clinical trials (12 November 2008, 10 October 2017, 3 July 2018, 11 September 2019).We included all randomised trials comparing maintenance treatment with antipsychotic drugs and placebo for people with schizophrenia or schizophrenia-like psychoses.We extracted data

2020 Cochrane

2. Paliperidone - maintenance treatment of schizophrenia

Paliperidone - maintenance treatment of schizophrenia Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/277302/2020 EMEA/H/C/005486 Paliperidone Janssen-Cilag International (...) (paliperidone) An overview of Paliperidone Janssen-Cilag International and why it is authorised in the EU What is Paliperidone Janssen-Cilag International and what is it used for? Paliperidone Janssen-Cilag International is an antipsychotic medicine used for the maintenance treatment of schizophrenia in adults whose disease has already been stabilised on treatment with paliperidone or risperidone. Some patients whose symptoms have not yet been stabilised may still be given Paliperidone Janssen- Cilag

2020 European Medicines Agency - EPARs

3. Avatar Therapy for people with schizophrenia or related disorders. (Abstract)

Avatar Therapy for people with schizophrenia or related disorders. Many people with schizophrenia do not achieve satisfactory improvements in their mental state, particularly the symptom of hearing voices (hallucinations), with medical treatment.To examine the effects of Avatar Therapy for people with schizophrenia or related disorders.In December 2016, November 2018 and April 2019, the Cochrane Schizophrenia Group's Study-Based Register of Trials (including registries of clinical trials (...) ) was searched, review authors checked references of all identified relevant reports to identify more studies and contacted authors of trials for additional information.All randomised clinical trials focusing on Avatar Therapy for people with schizophrenia or related disorders.We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and 95% confidence intervals (CI), on an intention-to-treat basis. For continuous data, we estimated the mean difference (MD) between groups and 95

2020 Cochrane

4. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. (Abstract)

A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. An oral compound, SEP-363856, that does not act on dopamine D2 receptors but has agonist activity at trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A) receptors, may represent a new class of psychotropic agent for the treatment of psychosis in schizophrenia.We performed a randomized, controlled trial to evaluate the efficacy and safety of SEP-363856 in adults with an acute exacerbation (...) of schizophrenia. The patients were randomly assigned in a 1:1 ratio to receive once-daily treatment with SEP-363856 (50 mg or 75 mg) or placebo for 4 weeks. The primary end point was the change from baseline in the total score on the Positive and Negative Symptom Scale (PANSS; range, 30 to 210; higher scores indicate more severe psychotic symptoms) at week 4. There were eight secondary end points, including the changes from baseline in the scores on the Clinical Global Impressions Severity (CGI-S) scale

2020 NEJM

5. Lumateperone tosylate (Caplyta) - schizophrenia

Lumateperone tosylate (Caplyta) - schizophrenia Drug Approval Package: CAPLYTA CAPLYTA " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: CAPLYTA Company: Intra-Cellular Therapies, Inc Application Number: 209500 Approval Date: 12/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

6. Treatment of Patients with Schizophrenia

Treatment of Patients with Schizophrenia This guideline is undergoing copyediting and the final version is expected to be released summer 2020. THE AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA Guideline Writing Group George A. Keepers, M.D. (Chair) Laura J. Fochtmann, M.D., M.B.I. (Vice-Chair; Methodologist) Joan M. Anzia, M.D. Sheldon Benjamin, M.D. Jeffrey M. Lyness, M.D. Ramin Mojtabai, M.D. Mark Servis, M.D. Art Walaszek, M.D. Peter (...) Schizophrenia 18 Implementation 18 Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement 31 Review of Available Guidelines from Other Organizations 32 Quality Measurement Considerations 32 Statement 2: Use of Quantitative Measures 33 Implementation 33 Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement 36 Review of Available Guidelines from Other Organizations 38 Quality Measurement Considerations 38 Statement 3: Evidence-based

2020 American Psychiatric Association

7. Evidence-based guidelines for the pharmacological treatment of schizophrenia

Evidence-based guidelines for the pharmacological treatment of schizophrenia The British Association for Psychopharmacology | BAP Consensus Guidelines – Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology Email Address: Password: Keep me logged in for 24 hours | Menu About Us Join BAP Members' Area Publications Meetings Education and Training Prizes and Awards Prizes and Awards Bursaries (...) > > Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology Please note that COPYRIGHT in the paper is owned by the British Association for Psychopharmacology (BAP). SINGLE ISSUE USE ONLY (and printing) for PERSONAL RESEARCH ONLY is acceptable. Information

2020 British Association for Psychopharmacology

8. Psychosis and schizophrenia: Drug interactions

Psychosis and schizophrenia: Drug interactions Interactions | Prescribing information | Psychosis and schizophrenia | CKS | NICE Search CKS… Menu Interactions Psychosis and schizophrenia: Drug interactions Last revised in January 2020 Drug interactions The following interactions are common to all antipsychotics: Drugs with a sedative action (such as alcohol, analgesics, tricyclic antidepressants, and sedating antihistamines) will enhance the sedative effects of antipsychotics. Drugs

2020 NICE Clinical Knowledge Summaries

9. Psychosis and schizophrenia: Available antipsychotics

Psychosis and schizophrenia: Available antipsychotics Available antipsychotics | Prescribing information | Psychosis and schizophrenia | CKS | NICE Search CKS… Menu Available antipsychotics Psychosis and schizophrenia: Available antipsychotics Last revised in January 2020 Available antipsychotics Antipsychotics are available as oral preparations or depot injections. They are classified as first-generation antipsychotics (typical) and second-generation antipsychotics (atypical). For more

2020 NICE Clinical Knowledge Summaries

10. Psychosis and schizophrenia: Adverse effects

Psychosis and schizophrenia: Adverse effects Adverse effects | Prescribing information | Psychosis and schizophrenia | CKS | NICE Search CKS… Menu Adverse effects Psychosis and schizophrenia: Adverse effects Last revised in January 2020 Adverse effects Antipsychotics can cause a wide range of adverse effects — the risk varies with the type of antipsychotic (first-generation or second-generation) and the individual drug. CKS recommends that people who may benefit from a dose reduction (...) as: A small, steady increase in blood pressure over time (may be associated with weight gain), or An unpredictable, sharp increase in blood pressure on starting a new drug. Reduced seizure threshold — seizures are a recognized adverse effect of antipsychotics (the higher the dose, the greater the risk). Clozapine carries the greatest risk. Impaired glucose tolerance — more common in people with schizophrenia than in the general population, and has been associated with both first-generation and second

2020 NICE Clinical Knowledge Summaries

11. Psychosis and schizophrenia

Psychosis and schizophrenia Psychosis and schizophrenia | Topics A to Z | CKS | NICE Search CKS… Menu Psychosis and schizophrenia Psychosis and schizophrenia Last revised in January 2020 Psychosis is a disordered mental state characterized principally by positive symptoms such as hallucinations, delusions, and thought disorder. Diagnosis Management Prescribing information Background information Psychosis and schizophrenia: Summary The term 'psychosis' encompasses a number of symptoms associated (...) are cardinal features of psychotic disorders, the most common of which is schizophrenia, but may also be caused acutely by certain medicines, substance misuse, and by some medical conditions such as sepsis. With treatment, psychotic symptoms as a feature of a psychotic disorder may resolve fully, recur intermittently with periods of remission between, or persist. Complications of psychotic disorders include: An increased risk of premature death due higher rates of suicide, cardiovascular disease, and type

2020 NICE Clinical Knowledge Summaries

12. Modafinil for people with schizophrenia or related disorders. (Abstract)

Modafinil for people with schizophrenia or related disorders. People with schizophrenia have a range of different symptoms, including positive symptoms (hallucinations and delusions), negative symptoms (such as social withdrawal and lack of affect), and cognitive impairment. The standard medication for people with schizophrenia is antipsychotics. However, these medications may not be effective for all symptoms of schizophrenia, as cognitive and negative symptoms are usually hard to treat (...) . Additional therapies or medications are available for the management of these symptoms. Modafinil, a wakefulness-promoting agent most frequently used in narcolepsy or shift work sleep disorder, is one intervention that is theorised to have an effect of these symptoms.The primary objective of this review was to assess the effects of modafinil for people with schizophrenia or related disorders.On 27 April 2015, 24 May 2017, and 31 October 2019, we searched the Cochrane Schizophrenia Group's register

2019 Cochrane

13. Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial (Abstract)

Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial Negative symptoms represent a substantial burden in schizophrenia. Although preliminary studies have suggested that transcranial direct current stimulation (tDCS) is effective for some clusters of symptoms, the clinical benefits for negative symptoms are unclear.To determine the efficacy and safety of tDCS vs sham as an add-on treatment for patients (...) with schizophrenia and predominant negative symptoms.The double-blind Schizophrenia Treatment With Electric Transcranial Stimulation (STARTS) randomized clinical trial was conducted from September 2014 to March 2018 in 2 outpatient clinics in the state of São Paulo, Brazil. Patients with schizophrenia with stable negative and positive symptoms and a minimum score of 20 points in the negative symptoms subscale of the Positive and Negative Syndrome Scale (PANSS) were included.Ten sessions of tDCS performed twice

2019 EvidenceUpdates

14. Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness

Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Atypical Injectable Antipsychotics for Schizophrenia (...) or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: January 3, 2019 Project Number: RC1053-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of atypical long-acting injectable antipsychotics for the treatment of patients with schizophrenia or bipolar disorder? What is the cost-effectiveness of atypical long-acting injectable antipsychotics for the treatment of patients

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT Full Text available with Trip Pro

Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Minocycline had no effect on negative symptoms of schizophrenia and had no effect on any of the biomarkers of inflammation or neurodegeneration. {{author}} {{($index , , , , , , , , , , , , , , , , , & . Bill Deakin 1, 2, 3, * , John Suckling 4, 5 , Paola Dazzan 6 , Eileen Joyce 7 , Stephen M Lawrie 8 , Rachel Upthegrove 9 , Nusrat Husain 10, 11 , Imran B Chaudhry 11, 12 , Graham Dunn 13, † , Peter B Jones 4

2019 NIHR HTA programme

16. Acetylsalicylic acid (aspirin) for schizophrenia. (Abstract)

Acetylsalicylic acid (aspirin) for schizophrenia. Schizophrenia is a serious chronic mental illness affecting an estimated 21 million people worldwide and there is increasing evidence linking inflammation in the brain to the pathophysiology of schizophrenia. Antipsychotic drugs are the conventional treatment for people with schizophrenia but are not always fully effective. Acetylsalicylic acid (aspirin) is a non-steroidal anti-inflammatory drug (NSAID) with properties that inhibit (...) the proinflammatory status of the brain. Using aspirin as an adjunct (add-on) treatment to antipsychotics or as a stand-alone treatment could be a novel, relatively inexpensive option for people with schizophrenia.To review the effects of acetylsalicylic acid (aspirin) as adjunct (add-on) or as stand-alone treatment for people with schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (last search 8 March 2018) which is based on regular searches of MEDLINE, Embase, PubMed, CINAHL, BIOSIS

2019 Cochrane

17. Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. (Abstract)

Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. Catatonia is a debilitating disorder of movement and volition associated with schizophrenia and some other mental illnesses. People with catatonia are more likely to require hospitalisation and highly supervised care than those without the disorder. They also have an increased risk of secondary complications such as pneumonia, malnutrition and dehydration. The mainstay of treatment has been drug (...) therapies and electroconvulsive therapy.To compare the effects of benzodiazepines with other drugs, placebo or electroconvulsive therapy for catatonia in people with schizophrenia or other similar serious mental illnesses (SMIs).We updated our previous search (28 February 2007) by searching the Cochrane Schizophrenia Group's Study-Based Register of Trials (9 November 2016; 6 February 2019). This register is compiled by systematic searches of major resources (including CENTRAL, MEDLINE, Embase, AMED

2019 Cochrane

18. Brexpiprazole (Rxulti) for the treatment of schizophrenia in adults

Brexpiprazole (Rxulti) for the treatment of schizophrenia in adults Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults | Report | National Health Care Institute You are here: Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults Search within English part of National Health Care Institute Search Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults Zorginstituut Nederland carried out a marginal assessment whether the product brexpiprazole (Rxulti® (...) ) can be accepted into the Medicine Reimbursement System (GVS). Registration Brexpiprazole (Rxulti®), an antipsychotic, is registered and indicated for the treatment of schizophrenia in adults. Zorginstituut's advice Based on the criteria for interchangeability, we conclude that brexpiprazole (Rzulti®) is interchangeable with the other drugs in GVS cluster N405AXAO V, which includes: aripiprazole, cariprazine, paliperidone, quetiapine and risperidone. A standard dose of 3 mg can be established

2019 National Health Care Institute (Zorginstituut Nederland)

19. Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial Full Text available with Trip Pro

Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial Schizophrenia is a leading cause of disability, and a shift from facility- to community-based care has been proposed to meet the resource challenges of mental healthcare in low- and middle-income countries. We hypothesized that the addition of mobile texting would improve (...) schizophrenia care in a resource-poor community setting compared with a community-based free-medicine program alone.In this 2-arm randomized controlled trial, 278 community-dwelling villagers (patient participants) were randomly selected from people with schizophrenia from 9 townships of Hunan, China, and were randomized 1:1 into 2 groups. The program participants were recruited between May 1, 2015, and August 31, 2015, and the intervention and follow-up took place between December 15, 2015, and July 1

2019 EvidenceUpdates

20. Cariprazine (Reagila) for the treatment of schizophrenia in adult patients.

Cariprazine (Reagila) for the treatment of schizophrenia in adult patients. 1 Published 13 May 2019 1 SMC2137 cariprazine 1.5mg, 3mg, 4.5mg and 6mg hard capsules (Reagila®) Recordati Pharmaceuticals Ltd 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission cariprazine (Reagila® (...) ) is accepted for restricted use within NHSScotland. Indication under review: the treatment of schizophrenia in adult patients. SMC restriction: for use as a second-line therapy in patients where predominantly negative symptoms have been identified as an important feature. In patients with stable schizophrenia with predominantly negative symptoms, cariprazine improved negative symptoms more than another second-generation antipsychotic. Chairman Scottish Medicines Consortium www.scottishmedicines.or g.uk 2

2019 Scottish Medicines Consortium